Advanced glycation end products (AGEs) are formed as a result of non-enzymatic reaction
between the free reducing sugars and proteins, lipids, or nucleic acids. AGEs are …

Receptor for advanced glycation end products (RAGE) is an immunoglobulin-like receptor
present on cell surface. RAGE binds to an array of structurally diverse ligands, acts as a …

Interaction of RAGE (the receptor for advanced glycation endproducts) with its ligands can
promote tumor progression, invasion, and angiogenesis. Although blocking RAGE signaling …

Reducing sugars can react non-enzymatically with the amino groups of proteins, lipids, and
nucleic acids to initiate a complex series of rearrangements and dehydrations, and then to …

Ethnopharmacological relevance Zuojin pill (ZJP), a classical Chinese medicine formula,
has been widely applied in Chinese clinical practice for the treatment of gastric injury such …

Chronic hyperglycemia has been associated with an increased prevalence of pathological
conditions including cardiovascular disease, cancer, or various disorders of the immune …

Compelling shreds of evidence derived from both clinical and experimental research have
demonstrated the crucial contribution of receptor for advanced glycation end products …

The sclerostin domain containing protein 1 (SOSTDC1) is a cell signaling regulator involved
in cell physiology and pathology. SOSTDC1 is known to have a suppressive effect on certain …

Little is known about long non‐coding RNA (lncRNA) related to innate immunity in lung
cancer. The advanced glycosylation end‐product specific receptor (AGER) belongs to the …

Background The receptor for advanced glycation endproducts (RAGE) is an oncogenic
multidisciplinary trans-membranous receptor, which is overexpressed in multiple human …